Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Zhonghua Er Ke Za Zhi ; 62(6): 553-558, 2024 Jun 02.
Artigo em Chinês | MEDLINE | ID: mdl-38763878

RESUMO

Objective: To summarize the clinical characteristics, prognostic factors and treatment outcomes of childhood aggressive mature B-cell lymphoma after liver transplantation. Methods: This retrospective study included 18 children with newly diagnosed aggressive mature B-cell lymphoma after liver transplantation and treated from June 2018 to June 2022 in the Department of Hematology and Oncology of Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine. Clinical characteristics, treatment and outcomes of patients at last evaluation were analyzed. Overall survival (OS) and event free survival (EFS) rates were calculated by Kaplan-Meier method and Log-Rank analysis was performed to find factors of poor prognosis. Results: Among all 18 patients, there were 6 males and 12 females, and the age of onset was 40 (35, 54) months. The interval from transplant to tumor diagnosis was 21 (17, 35) months and 5 patients had early onset disease (<1 year since transplant). Seventeen patients had abdominal lesions. Diarrhea, vomiting and abdominal masses were the main clinical manifestations. All patients were Epstein-Barr virus (EBV) related posttransplant lymphoproliferative disorders (PTLD). One patient received individualized therapy due to critical sick at diagnosis, and the remaining 17 patients received CP (cyclophosphamide, methylprednisolone plus rituximab) and (or) modified EPOCH (prednisone, etoposide, doxorubicin, vincristine, cyclophosphamide plus rituximab) regimens. Of all 18 patients, 15 cases got complete response, 2 cases got partial response, 1 patient died of severe infection. The 2-year OS and EFS rates of 18 patients were (94±5)% and (83±8)%, respectively. None of age, gender or early onset disease had effect on OS and EFS rates in univariate analysis (all P>0.05). Conclusions: The symptoms of PTLD were atypical. Close surveillance of EBV-DNA for patients after liver transplantation was crucial to early stage PTLD diagnosis. CP or modified EPOCH regimen was efficient for pediatric patients with aggressive mature B cell lymphoma after liver transplantation.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica , Transplante de Fígado , Linfoma de Células B , Humanos , Transplante de Fígado/efeitos adversos , Feminino , Masculino , Estudos Retrospectivos , Pré-Escolar , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Criança , Linfoma de Células B/etiologia , Prognóstico , Ciclofosfamida/administração & dosagem , Ciclofosfamida/uso terapêutico , Infecções por Vírus Epstein-Barr/complicações , Infecções por Vírus Epstein-Barr/etiologia , Vincristina/uso terapêutico , Taxa de Sobrevida , Doxorrubicina/uso terapêutico , Doxorrubicina/administração & dosagem , Resultado do Tratamento , Prednisona/uso terapêutico , Prednisona/administração & dosagem , Herpesvirus Humano 4/isolamento & purificação , Transtornos Linfoproliferativos/etiologia , Lactente , Adolescente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA